Stockscreener 앱 받기
40.47
19.66%
6.65
시간 외 거래:
40.65
0.18
+0.44%
전일 마감가:
$33.82
열려 있는:
$34.15
하루 거래량:
11.73M
Relative Volume:
5.03
시가총액:
$4.30B
수익:
$761.41M
순이익/손실:
$98.16M
주가수익비율:
49.47
EPS:
0.8181
순현금흐름:
$141.79M
1주 성능:
+21.53%
1개월 성능:
+11.73%
6개월 성능:
-51.08%
1년 성능:
-30.61%
1일 변동 폭
$33.99
$50.40
1주일 범위
$32.89
$50.40
52주 변동 폭
$28.66
$117.33
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
40.47 | 3.60B | 761.41M | 98.16M | 141.79M | 0.8181 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-31 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | 개시 | UBS | Neutral |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-06 | 업그레이드 | Truist | Hold → Buy |
| 2023-04-11 | 개시 | SVB Securities | Market Perform |
| 2023-04-04 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-06-27 | 재개 | Canaccord Genuity | Buy |
| 2022-02-02 | 개시 | Canaccord Genuity | Buy |
| 2022-01-28 | 개시 | Truist | Buy |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-09-24 | 개시 | Jefferies | Buy |
| 2019-09-06 | 개시 | H.C. Wainwright | Buy |
| 2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 재확인 | Stifel | Hold |
| 2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 개시 | Stifel | Buy |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2015-04-21 | 개시 | FBR Capital | Outperform |
| 2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
| 2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
'Moments like this don't happen every day': Ovarian cancer drug from Peninsula company wins FDA approval - The Business Journals
Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday - The Globe and Mail
Corcept Therapeutics Receives FDA Approval for Lifyorli - Intellectia AI
Early FDA wins: Corcept’s Lifyorli, Denali’s Avlayah - BioWorld MedTech
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss - GlobeNewswire Inc.
[144] CORCEPT THERAPEUTICS INC SE... | CORT SEC FilingForm 144 - Stock Titan
CORT: HC Wainwright Lowers Price Target to $60, Maintains Buy Ra - GuruFocus
HC Wainwright Has Lowered Expectations for Corcept Therapeutics (NASDAQ:CORT) Stock Price - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Shares Up 10.3%What's Next? - MarketBeat
Corcept Therapeutics (CORT) Gains FDA Nod for Lifyorli in Cancer Treatment - GuruFocus
Corcept Therapeutics Sees Activity Surge as Insider Buys Boost Investor Confidence - StocksToTrade
FDA clears Corcept (CORT) Lifyorli combo for platinum-resistant ovarian cancer - Stock Titan
Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer - Reuters
FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer – Company AnnouncementFT.com - Financial Times
US Stocks: Corcept Therapeutics shares surge 32% as lead drug gets FDA nod for ovarian cancer - The Economic Times
Corcept Therapeutics (CORT) Sees Significant Surge Amid Market G - GuruFocus
Corcept Therapeutics Stock Soars as Insider Buys Spur Market Interest - timothysykes.com
Corcept Therapeutics (CORT) Gains as FDA Approves Cancer Drug - GuruFocus
What's Behind The Jump In Corcept Therapeutics Stock? - Benzinga
Corcept Therapeutics surges as investors focus on a sizable insider buy and relacorilant’s next regulatory catalyst - Quiver Quantitative
CORCEPT THERAPEUTICS INCORPORATED (CORT) - MSN
Corcept Therapeutics (CORT) Jumps 43% Following FDA Approval of Key Drug - GuruFocus
US FDA approves Corcept Therapeutics' drug for hard-to-treat ovarian cancer - marketscreener.com
Corcept Therapeutics (CORT) Surges 10% Following FDA Approval of Cancer Treatment - GuruFocus
FDA Approves Corcept Therapeutics' (CORT) New Cancer Treatment - GuruFocus
Corcept Therapeutics stock surges on FDA cancer drug approval By Investing.com - Investing.com Canada
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers - CancerNetwork
Deadline Approaching for Investors of Corcept Therapeutics, Inc. (CORT)Contact Kaplan Fox Before April 21, 2026 - The National Law Review
Corcept Therapeutics (NASDAQ:CORT) Insider Sells $423,729.67 in Stock - MarketBeat
Assessing Corcept Therapeutics (CORT) Valuation After Recent Share Price Weakness And User Fair Value Debate - Yahoo Finance
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - GlobeNewswire Inc.
Kaplan Fox Continues to Alert Investors of a Securities Class Act - The National Law Review
Corcept therapeutics exec Guyer sells $423,729 in shares By Investing.com - Investing.com Australia
CORT DEADLINE NOTICE: Corcept Therapeutics Incorporated - GlobeNewswire
Corcept therapeutics exec Guyer sells $423,729 in shares - Investing.com
[Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity - Stock Titan
Corcept (CORT) CDO exercises options and sells 11,767 shares - Stock Titan
Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately - Finviz
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Corcept - GlobeNewswire
CORT Shareholder Alert: April 21, 2026 Lead Plaintiff Deadline i - GuruFocus
CORT Shareholder Alert: April 21, 2026 Lead Plaintiff Deadline in Corcept Therapeutics Incorporated Securities Class Action Lawsuit -- The Gross Law Firm - PR Newswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Concorde International Group Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Levi & Korsinsky Reminds Corcept Therapeutics Incorporated - GlobeNewswire
Shareholders who lost money in shares of Corcept - GlobeNewswire
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud ... - Caledonian Record
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors - GlobeNewswire
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics IncorporatedCORT - Morningstar
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):